Skip to main content

Clinical Research

The Type 1 diabetes clinical research team at Indiana University School of Medicine is working to advance detection and treatment for people at all stages of diabetes development and progression.

The three main goals of the research team are to prevent disease development in people who are high risk, preserve beta cell function in newly diagnosed patients, and improve quality of life through technology and therapeutics in persons with established diabetes.

Clinical Research at IU School of Medicine

Learn more about the focus and phases of clinical research and explore additional active studies conducted by IU School of Medicine physician investigators.

Learn More

Diabetes Prevention

The Type 1 diabetes clinical research team screens first and second degree relatives of people with Type 1 diabetes to assess risk for disease. The purpose of screening is to identify opportunities for earlier disease intervention and possible prevention.

Preserving Beta Cell Function

Clinical trials to preserve beta cell function involve both adults and children with newly diagnosed Type 1 diabetes. Research in these studies aims to prolong the function and survival of the insulin-secreting beta cells by using different therapeutic agents.

Improve Quality of Life

Clinical trials to preserve beta cell function involve both adults and children with newly diagnosed Type 1 diabetes. Research in these studies aims to prolong the function and survival of the insulin-secretinType 1 diabetes is a serious chronic condition that must be constantly monitored by the patient or a caregiver. Clinical research at IU School of Medicine seeks to improve the quality of life for people with Type 1 diabetes and caregivers through the investigation of novel therapies, technology and delivery methods.g beta cells by using different therapeutic agents.

Active Studies

Currently, the clinical research team is conducting studies involving people who have a high risk for Type 1 diabetes, patients with newly diagnosed Type 1 diabetes and people with established Type 1 diabetes.

Questions or requests for additional information may be directed via email to a study coordinator.

Prevention and Early Intervention

  • Natural History Study Pathway to Prevention
    Study coordinator: Eric Grubbs, BS

    Open for enrollment: Yes

    The purpose of this observational study is to detect Type 1 diabetes at its earliest stages. Family members of people with Type 1 diabetes are screened for autoantibodies associated with Type 1.

  • Abatacept for the Prevention of Abnormal Glucose Tolerance
    Study coordinator: Megan Hildinger, RN, CCRP, CDE

    Open for enrollment: Yes

    Type 1 diabetes TrialNet tests the drug abatacept to determine its preventative effects on the progression of early stage Type 1 diabetes (stages 1 and 2) to clinical diagnosis (stage 3).

  • Hydroxychloroquine HCQ for the Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals AtRisk for Type 1 Diabetes Mellitus
    Study Coordinator: Megan Legge, CCRP

    Open for enrollment: Yes

    This is the first study to determine if hydroxychloroquine (HCQ), a drug commonly used for treatment of malaria, can prevent or delay Type 1 diabetes. Currently, HCQ is also used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus.

  • Identification of Beta Cell Dysfunction in Relatives of Type 1 Patients
    Study coordinator: Kelly Moors BS, BA

    Open for enrollment: Yes

    Type 1 diabetes occurs when the immune system destroys the insulin secreting beta cells of the pancreas over time.  The purpose of the Type 1 diabetes family study is to compare beta cell funcation between relatives of those with Type 1 diabetes to those without a family history of the condition.

Patients with Newly Diagnosed Type 1

  • SIMPONI to Arrest -cell Loss in Type 1 Diabetes
    Study coordinator: Megan Hildinger, RN, CCRP, CDE

    Open for enrollment: No

    The primary purpose of this study is to determine the effects of golimumab (Gleevec ®) to preserve beta-cell function in children and young adults with newly diagnosed Type 1 diabetes.

  • Preserving Beta-Cell Function with Tocilizumab in New-onset Type 1 Diabetes
    Study coordinator: Megan Hildinger, RN, CCRP, CDE

    Open for enrollment: No

    Tocilizumab is a drug used to treat certain autoimmune diseases. This study seeks to determine its effectiveness for preserving or delaying destruction of remaining beta cells in people with recently diagnosed Type 1 diabetes.

  • Polyamines Using DFMO in Persons with Type 1 Diabetes
    Study coordinator: Jillian Kapturowski, RN

    Open for enrollment: Yes

    This study is led by the Type 1 Diabetes Research team at IU School of Medicine with support from the Juvenile Diabetes Research Foundation.  It examines the use of difluoromethylornithine (DFMO) to treat people with Type 1 and its effectiveness in helping people produce their own insulin.

Patients with Established Type 1 Diabetes

  • Recruitment Database
    Study coordinator: America Newnum, MS, CCRP

    Open for enrollment: Yes

    With consent from participants, the Type 1 Diabetes Research Team collects and stores information to determine eligibility for future research studies. Participants may be contacted to see if they wish to participate.

  • Day and Night Closed Loop in Young People with Type 1 Diabetes
    Study coordinator: Megan Legge, CCRP

    Open for enrollment: Yes

    This is a study of a new pump/sensor combination ‘artificial pancreas’ system. The main study objective is to determine whether 24/7 automated closed-loop glucose control combined with a low glucose feature will improve glucose control as measured by HbA1c.

  • Afrezza in Children With Type 1 diabetes
    Study Coordinator: Megan Tebbe, TN, CCRP, CDE

     

    Open for Enrollment: Yes

    Afrezza © is an inhaled insulin that replaces short-acting insulin injections, and is already approved for use in adults. The primary purpose of this study is to assess the safety and efficacy of Afrezza © in children with Type 1 diabetes.